美國居民不適用 XM 服務。
C
C

Cigna


財經新聞

Cigna's medical use trends in line with projections for 2023, 2024 -GS conference

UPDATE 1-Cigna's medical use trends in line with projections for 2023, 2024 -GS conference Adds details from the conference call throughout By Amina Niasse and Pratik Jain NEW YORK, June 11 (Reuters) - Health insurer Cigna's CI.N medical use trends across its portfolio were in line with its expectations for 2023 and 2024, CFO Brian Evanko said on Tuesday, citing the company's lack of Medicaid management.
C
G

UnitedHealth hack impacted outpatient claims for Cigna - GS conference

UnitedHealth hack impacted outpatient claims for Cigna - GS conference NEW YORK, June 11 (Reuters) - Cigna's CFO Brian Evanko said the company's "outpatient dynamic" was impacted by the Change Healthcare hack which disrupted claims during the first quarter of 2024. The February ransomware attack on the largest U.S. insurer stole a "substantial portion" of personal data from American patients and disrupted provider payments.
C

AbbVie's tight grip on Humira market raises concerns about biosimilars

FOCUS-AbbVie's tight grip on Humira market raises concerns about biosimilars By Patrick Wingrove June 7 (Reuters) - AbbVie’s ABBV.N top-selling arthritis drug Humira has held onto more than 80% of patients after facing nine lower-priced rivals in the U.S. in the last year, raising questions about whether the market for prescription biosimilars can survive in its current form, drug pricing experts and analysts say.
A
C
P
T
F

U.S. Elevance Health, Wesco International, WW Grainger

U.S. RESEARCH ROUNDUP-Elevance Health, Wesco International, WW Grainger May 30 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.listed companies including Elevance Health, Wesco International and WW Grainger, on Thursday. HIGHLIGHTS * Cigna Group CI.N : JP Morgan raises target price to $435 from $432 * Elevance Health Inc ELV.N : JP Morgan raises target price to $631 from $628 * Uipath Inc PATH.N : TD Cowen cuts to hold from buy * Wesco Internati
A
C
C
E
F
S
A
E
H
W
A
L
U

U.S. AMC Networks, Permian Resources, Vital Energy

U.S. RESEARCH ROUNDUP-AMC Networks, Permian Resources, Vital Energy May 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including AMC Networks, Permian Resources and Vital Energy, on Monday. HIGHLIGHTS * AMC Networks AMCX.O : Moffettnathanson cuts target price by $1 to $13 * Celanese Corp CE.N : Jefferies raises target price to $170 from $155 * Permian Resources Corp PR.N : Gerdes Energy Research raises to buy from neutral
A
B
C
G
H
A
A
A
U
A
A
C

Teva Pharm to launch Humira biosimilar as Q1 profit misses estimates

CORRECTED-UPDATE 2-Teva Pharm to launch Humira biosimilar as Q1 profit misses estimates Corrects in paragraph 6 to say Cigna and Optum are covering two or three Humira biosimilars By Steven Scheer JERUSALEM, May 8 (Reuters) - Teva Pharmaceutical Industries TEVA.TA said it was set to launch its long awaited biosimilar of AbbVie's ABBV.N blockbuster arthritis drug Humira in the coming weeks after it posted mixed results in the first three months of 2024. The drugmaker also said late-stage results
C
T

U.S. Berkshire Hathaway, Parker-Hannifin, Quaker Houghton

U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Parker-Hannifin, Quaker Houghton May 6 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Berkshire Hathaway, Parker-Hannifin and Quaker Houghton, on Monday. HIGHLIGHTS * Berkshire Hathaway BRKa.N : KBW raises target price to $660,000 from $645,000 * Essex Property Trust Inc ESS.N : Piper Sandler raises target price to $315 from $291 * Parker-Hannifin Corp PH.N : Jefferies cuts
A
C
E
G
E
C
C

U.S. Paramount Global, Sprout Social, Williams-Sonoma

U.S. RESEARCH ROUNDUP- Paramount Global, Sprout Social, Williams-Sonoma May 3 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Paramount Global, Sprout Social and Williams-Sonoma ,on Friday. HIGHLIGHTS * Expedia Group Inc EXPE.O : Piper Sandler cuts to neutral from overweight * Paramount Global PARA.O : Seaport Research Partners cuts to neutral from buy * Sprout Social Inc SPT.O : Piper Sandler cuts to neutral from ov
A
A
B
B
C
E
F
H
S
D
T
B
Z
A
B
C
M
T

Cigna Says Regulatory Review By U.S. DOJ Of Medicare Business Sale Is Complete

BRIEF-Cigna Says Regulatory Review By U.S. DOJ Of Medicare Business Sale Is Complete May 2 (Reuters) - Cigna Group CI.N : CIGNA EXEC SAYS REGULATORY REVIEW BY THE US DOJ OF CO'S DEAL TO SELL MEDICARE BUSINESS TO HEALTH CARE SERVICE CORP IS COMPLETE - CONF CALL CIGNA EXEC SAYS CO SAW "SOME DISRUPTION TO CLAIM SUBMISSIONS AND PAYMENTS" IN Q1 DUE TO C
C

Cigna Group reports results for the quarter ended in March - Earnings Summary

Cigna Group reports results for the quarter ended in March - Earnings Summary Cigna Group CI.N reported quarterly adjusted earnings of $6.47​​ per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of $5.41. The mean expectation of twenty two analysts for the quarter was for earnings of $6.22 per share.
C

Cigna lifts annual profit view on lower medical costs, pharmacy benefit strength

UPDATE 2-Cigna lifts annual profit view on lower medical costs, pharmacy benefit strength Adds analyst comment in paragraph 5, change cyberattack details in paragraphs 8 and 9 By Bhanvi Satija May 2 (Reuters) - Cigna Group CI.N raised its annual profit forecast on Thursday, helped by lower-than-expected medical costs and strength in its pharmacy benefit management unit.
C

Fed QT taper calms the horses, yen pops again

MORNING BID AMERICAS-Fed QT taper calms the horses, yen pops again A look at the day ahead in U.S. and global markets from Mike Dolan Anxious bond traders seem to have taken solace from the Federal Reserve's surprisingly sharp brake on its "quantitative tightening" process on Wednesday, while the yen capitalized on an easier dollar after what seemed like the second bout of Japanese intervention this week.
A
A
A
C
E
H
I
R
S
U
A
U
I
V
W
Z
A
B
D
H
I
L
P
P
P
T

Cigna sees strong annual profit on lower costs, pharmacy benefit strength

Cigna sees strong annual profit on lower costs, pharmacy benefit strength May 2 (Reuters) - Health insurer Cigna Group CI.N raised its annual profit forecast on Thursday, as lower-than-expected medical costs and strength in its pharmacy benefit management unit helped it beat first-quarter earnings estimates. The company now expects an adjusted profit of at least $28.40 per share in 2024, up 15 cents from its previous forecast.
C

What to Watch in the Day Ahead - Thursday, May 2

What to Watch in the Day Ahead - Thursday, May 2 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT Apple's revenue is expected to decline 5% and would mark the fifth instance of topline drop in the past six quarters as demand for its chief commodity the iPhone as well Mac computers remains weak.
A
A
C
E
I
K
R
C
B
W
A
L
P
P

Cigna Group <CI.N> expected to post earnings of $6.22 a share - Earnings Preview

Cigna Group expected to post earnings of $6.22 a share - Earnings Preview Cigna Group CI.N , CI is expected to show a rise in quarterly revenue when it reports results on May 2 for the period ending March 31 2024 The Bloomfield Connecticut-based company is expected to report a 21.6% increase in revenue to $56.517 billion from $46.48 billion a year ago, according to the mean estimate from 16 analysts, based on LSEG data.
C

Drugmaker AbbVie expects Humira volume erosion to worsen

UPDATE 4-Drugmaker AbbVie expects Humira volume erosion to worsen Adds analyst comment in paragraph 7, background on Cigna's Humira plans in paragraph 6, updates shares By Leroy Leo and Christy Santhosh April 26 (Reuters) - AbbVie ABBV.N expects a drop in sales volumes of its blockbuster arthritis drug Humira to deepen after recent changes by U.S. pharmacy benefit managers and as patients shift to other drugs.
C

Cigna to offer Humira rivals with $0 copay at specialty pharmacy

Cigna to offer Humira rivals with $0 copay at specialty pharmacy By Patrick Wingrove and Amina Niasse April 25 (Reuters) - Cigna CI.N plans to make close copies of AbbVie's ABBV.N blockbuster arthritis drug Humira available with no out-of-pocket payment to eligible patients in the U.S. using its specialty pharmacy beginning in June, the health insurer said on Thursday.
C
N
T

The Cigna Group Declares Quarterly Dividend

BRIEF-The Cigna Group Declares Quarterly Dividend April 24 (Reuters) - Cigna Group CI.N : THE CIGNA GROUP DECLARES QUARTERLY DIVIDEND CIGNA GROUP - DECLARED A CASH DIVIDEND OF $1.40 PER SHARE OF ITS COMMON STOCK Source text for Eikon: ID:nPncbdzC1a Further company coverage: CI.N
C

U.S. STOCKS AZZ, Vanda Pharma, Matterport

BUZZ-U.S. STOCKS ON THE MOVE-AZZ, Vanda Pharma, Matterport Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stocks rose on Monday in choppy trading after steep losses in the previous session as easing Middle East tensions buoyed risk appetite, while investors looked ahead to an action-packed week with major tech earnings and a key inflation print.
C
M
N
S
T
V
Z
U
U
U

U.S. STOCKS AZZ, Smartsheet, Zions Bancorporation

BUZZ-U.S. STOCKS ON THE MOVE-AZZ, Smartsheet, Zions Bancorporation Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes rose on Monday after steep losses in the previous session as easing Middle East tensions buoyed risk appetite, while investors looked ahead to an action-packed week with major tech earnings and a key inflation print.
C
N
S
T
V
Z
U
U
U



細節

熱門資產

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。